That made it the largest contributor to Merck's total quarterly sales of $16.1 billion. Ongoing clinical trials and further ...

What separates KL-50 from other chemotherapy drugs is its remarkable selectivity ... it was fundraising,” Lin told the News.

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

German sci-tech giant Merck is very optimistic about its prospects in the Chinese market and will continue to strengthen its ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely, as Merck's future hinges on new drug developments amid looming patent expirations. Keytruda is now under ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies ... category Fed's Kugler ...

Since 2017, Merck (known as MSD outside of the U.S. and Canada ... the medicines with high coverage demonstrating effectiveness of triple drug therapy, and the partners who made elimination of LF in ...